The fifth edition of the World Health Organization (WHO) classification of urogenital tumours
(WHO “Blue Book”), published in 2022, contains significant revisions. This review …

The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and
progression are being increasingly defined. The TRACERx Renal studies and others that …

Liquid chromatography (LC) coupled with data-independent acquisition (DIA) mass
spectrometry (MS) has been increasingly used in quantitative proteomics studies. Here, we …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA)
using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic …

Clear cell renal cell carcinomas (ccRCCs) represent∼ 75% of RCC cases and account for
most RCC-associated deaths. Inter-and intratumoral heterogeneity (ITH) results in varying …

Mass-spectrometry-based proteomic data on human tumors—combined with corresponding
multi-omics data—present opportunities for systematic and pan-cancer proteogenomic …

Genomic analyses in cancer have been enormously impactful, leading to the identification of
driver mutations and development of targeted therapies. But the functions of the vast majority …

To the Editor—Here we introduce Philosopher (https://philosopher. nesvilab. org), a free,
open-source, versatile and robust data analysis toolkit designed to bring easy access to a …

The proteome provides unique insights into disease biology beyond the genome and
transcriptome. A lack of large proteomic datasets has restricted the identification of new …